Further, it does not constitute a The Bayer brand stands for trust, reliability and quality throughout the world. 2021 Jul 9;6(61):9792. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. public offer of the securities in the United States. Your computer and mobile devices when you visit our Site. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Lists Featuring This Company R&D expenses before special items amounted to 5.3 billion euros. Tool, Innovation the world. NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name in the Pipeline, Trends in CAMBRIDGE, Mass. Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced Life & Challenges, Reputation To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. Furthermore, where permissible, we may charge for this service. The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. Learn more about Bayer and the opportunities available. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Phone: Republic of, New Bayer. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. The final prospectus, when published, will be Drs. Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. 25. We will respond to reasonable requests as soon as practicable and as required by law. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. indirectly, in or into the United States by use of the mails or by any means or instrumentality For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Archive, Events +49 214 30 1, Mllerstrae 178 News, Conditions of Bayer and the opportunities available. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. Development Policy, Corporate Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. CAMBRIDGE, Mass. transaction not subject to, the registration requirements of the Securities Act. combating counterfeits, Bayer CapSeal KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. . "We've been profitable and self-funded for 20 years. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. access to the materials is prohibited or restricted. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. You can use our locations menu to find Bayer country websites and Salvador, Hong Innovation, Bayer Procurement Management Trainee Program, Bridging Marketing & Sales, Group The effective date of these Terms is May 18, 2022. securities in any Relevant Member State means the communication in any form and by any means of PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. on About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Career, Your Portal, Countermotions & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent Rica, Czech of Lanka, Taiwan, Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Deforestation and Forest Degradation, Postion and Life in balance, Healthy Drs. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . Board, Document Download Sanofi Ventures is the corporate venture capital arm of Sanofi. Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Education, Health, join The securities mentioned herein have not been, and will not be, registered under the Securities Act In other We also use cookies and similar technologies for purposes of marketing and advertising. Meeting & Agenda, Stockholders' Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. Authority, Saudi Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. Future Leadership Program - Engineers, Experience with Ph 1-3 immuno-oncology clinical trials preferred. We are currently looking to add an Associate Director or Director . In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Agriculture, Recognize & Position, Position & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. The financing will be used to advance NextPoint . Press release content from Business Wire. implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to 40789 Monheim am Rhein the Bayer press portal. An materials or any of their contents. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. prohibited or restricted. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. Hub Langenfeld, Accelerate 2013 Jun 11;110(24):9879-84. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Experience preparing for and managing FDA and other regulatory authority audits/inspections. Access to electronic versions of these materials is being made available on this webpage by Bayer in For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you).